Meeting
2013 ASCO Quality Care Symposium
Application of a novel method weighing drug costs against survival in castrate-resistant prostate cancer cancer.
Authors
Helmy M. Guirgis
University of California, Irvine, Irvine, CA
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Practice of Quality and Health Reform
Track
Practice of Quality,Health Reform: Implications for Costs and Quality
Sub Track
Measuring Value and Costs
Citation
J Clin Oncol 31, 2013 (suppl 31; abstr 271)
Abstract #
271
Poster Bd #
G6
Abstract Disclosures
Similar Posters
Poster
2013 Genitourinary Cancers Symposium
Novel methodology for cost evaluation of anticancer drugs in castrate-resistant prostate cancer.
First Author: Helmy M. Guirgis
Poster
2023 ASCO Genitourinary Cancers Symposium
Racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-resistant prostate cancer.
First Author: Maral DerSarkissian
Poster
2022 ASCO Genitourinary Cancers Symposium
Statin type and survival of patients with metastatic castrate-resistant prostate cancer receiving abiraterone and enzalutamide: A nationwide retrospective cohort study.
First Author: Harrison Yoon
Poster
2020 Genitourinary Cancers Symposium
New patient-derived models of castrate-sensitive and castrate-resistant prostate cancer.
First Author: Mitchell Lawrence